Join Growin Stock Community!
Beta
Back to RXRX.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
revenue-chart

RXRX Revenue

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for RXRX's revenue in Q1'26 shows $6.47M USD, marking a decline from the previous quarter's $35.54M USD in Q4'25 and reflecting a year-over-year growth of -56.1%. This represents a significant drop, potentially indicating seasonal or operational challenges in the most recent period. Over the timeframe from Q2'23 to Q1'26, RXRX's revenue has exhibited volatile trends with an overall upward trajectory, starting at $11.02M USD and peaking at $35.54M USD in Q4'25, driven by notable surges such as a 147.6% YoY growth in Q3'24 and a remarkable 681.7% YoY increase in Q4'25. However, the chart reveals inconsistent patterns, including declines in Q3'23 (-20.0% YoY), Q4'24 (-58.3% YoY), Q3'25 (-80.2% YoY), and Q1'26, interspersed with growth periods like Q2'24 (30.9% YoY) and Q2'25 (33.3% YoY), suggesting potential instability in revenue streams possibly tied to project-based or market-dependent factors in the biotech sector.